The role of probiotics and natural bioactive compounds in modulation of the common molecular pathways in pathogenesis of atherosclerosis and cancer

Biologia

Volumn 67, Issue 1, 2012, Pages 1-13

  Bomba, Alojz ^a   Brandeburová, Andrea ^a   Ričanyová, Júlia ^a   Strojný, Ladislav ^a   Chmelárová, Anna ^a   Szabadosová, Viktória ^a   Pramuková, Beáta ^a   Žofčáková, Jana ^a   Salaj, Rastislav ^a   Supuková, Anna ^a   Čokášová, Denisa ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

atherosclerosis; cancer; natural bioactive compounds; probiotics

Indexed keywords

ANIMALIA;

EID: 84855574265     PISSN: 00063088     EISSN: 13369563     Source Type: Journal    
DOI: 10.2478/s11756-011-0155-6     Document Type: Review

References (120)

1. Akhurst R. J. & Derynck R. 2001. TGF-β signaling in cancer - double-edged sword. Trends Cell Biol. 11: 544-551.
2. Al-Sereiti M. R., Abu-Amer K. M. & Sen P. 1999. Pharmacology of rosemary (Rosmarinus officinalis Linn.) and its therapeutic potentials. Indian J. Exp. Biol. 37: 124-130.
3. Basseres D. S. & Baldwin A. S. 2006. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817-6830.
4. Bengmark S. 1998. Ecological control of the gastrointestinal tract: the role of probiotic flora. Gut 42: 2-7.
5. Benno Y. & Mitsuoha T. 1992. Impact of Bifidobacterium longum on human fecal microflora. Microbiol. Immunol. 36: 683-694.
6. Bergers G., Brekken R., McMahon G., Vu T. H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z. & Hanahan D. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 10: 737-744.
7. Bertková I., Hijová E., Chmelárová A., Mojžišová G., Petrášová D., Strojný L., Bomba A. & Žitňan R. 2010. The effect of probiotic microorganisms and bioactive compounds on chemically induced carcinogenesis in rats. Neoplasma 57: 422-428.
8. Beylot M. 2005. Effects of inulin-type fructans on lipid metabolism in man and in animal models. Br. J. Nutr. 93(Suppl. 1): 163-168.
9. Bingham M. 2006. The metabolism of polyphenols by the human gut microbiota, pp. 379-397. In: Ouwehand A. C. & Vaughan E. E. (eds) Gastrointestinal Microbiology. Taylor & Francis, New York.
10. Blankesteijn W. M., van Gijn M. E., Essers-Janssen, Daemen M. J. & Smits J. F. 2000. β-Catenin, an inducer of uncontrolled cell proliferation and migration in malignancies, is localized in the cytoplasm of vascular endothelium during neovascularization after myocardial infarction. Am. J. Pathol. 157: 877-883.
11. Blobe G. C, Schiemann W. P & Lodish H. F. 2000. Role of transforming growth factor β in human disease. N. Engl. J. Med. 342: 1350-1358.
12. Bomba A., Jonecová Z., Koščová J., Nemcová R., Gancarčíková S., Mudroňová D., Sciranková Ľ., Buleca V., Lazar G., Pošivák J., Kašteľ R. & Mareková M. 2006. The improvement of probiotic efficacy by synergistically acting components of natural origin: a review. Biologia 61: 729-734.
13. Bomba A., Nemcová R., Gancarčíková S., Herich R., Pistl J., Révajová V., Jonecová Z., Bugarský A., Levkut M., Kašteľ R., Baran M., Lazar G., Hluchý M., Maršálková S. & Pošivák J. 2003. The influence of ω-3 polyunsaturated fatty acids (ω-3 PUFA) on lactobacilli adhesion to the intestinal mucosa and on immunity in gnotobiotic piglets. Berl. Munch. Tierarztl. Wochenschr. 116: 312-316.
14. Bommareddy A., Arasada B. L., Mathees D. P. & Dwivedi C. 2006. Chemopreventive effects of dietary flaxseed on colon tumour development. Nutr. Cancer 54: 216-222.
15. Brady L. J., Gallaher D. D. & Busta F. F. 2000. The role of probiotic cultures in the prevention of colon cancer. J. Nutr. 130: 410-414.
16. Busserolles J., Gueux E., Rock E., Demigne C., Mazur A. & Rayssiguier Y. 2003. Oligofructose protects against the hypertriglyceridemic and pro-oxidative effects of a high fructose diet in rats. J. Nutr. 133: 1903-1908.
17. Calder P. C. 1998. Fat chance of immunomodulation. Immunol. Today 19: 244-247.
18. Catapano A. L. 1997. Antioxidant effects of flavonoids. Angiology 48: 39-44.
19. Cavallini D. C., Bedani R., Bomdespacho L. Q., Vendramini R. C. & Rossi E. A. 2009. Effects of probiotic bacteria, isoflavones and simvastatin on lipid profile and atherosclerosis in cholesterol-fed rabbits: a randomized double-blind study. Lipids Health Dis. 8: 1-8.
20. Chang G., Shi Y., Le G., Xu Z., Sun J. & Li J. 2009. Effects of Lactobacillus plantarum on genes expression pattern in mice jejunal Peyer's patches. Cell. Immunol. 258: 1-8.
21. Commane D., Hughes R., Shortt C. & Rowland I. 2005. The potential mechanism involved in the anti-carcinogenic action of probiotics. Mutat. Res. 591: 276-289.
22. Curin Y. & Andriantsitohaina R. 2005. Polyphenols as potential therapeutical agents against cardiovascular diseases. Pharmacol. Rep. 57(Suppl.): 97-107.
23. Dabek J., Kulach A. & Gasior Z. 2010. Nuclear factor κ-lightchain-enhancer of activated B cells (NF-κB): a new potential therapeutic target in atherosclerosis? Pharmacol. Reports 62: 778-783.
24. Das U. N. 2002. Essential fatty acids as possible enhancers of the beneficial actions of probiotics. Nutrition 18: 786-789.
25. De Santis A., Famularo G. & De Simone C. 2000. Probiotics for the hemodynamic alterations of patients with liver cirrhosis. Am. J. Gastroenterol. 95: 323-324.
26. Dickson M. C., Martin J. S., Cousins F. M., Kulkarni A. B., Karlsson S. & Akhurst R. J. 1995. Defective haematopoiesis and vasculogenesis in transforming growth factor-β 1 knock out mice. Development 121: 1845-1854.
27. Dollery C. M., McEwan J. R. & Henney A. M. 1995. Matrix metalloproteinases and cardiovascular disease. Circ. Res. 77: 863-868.
28. Dupertuis Y. M., Meguid M. M. & Pichard C. 2007. Colon cancer therapy: new perspectives of nutritional manipulations using polyunsaturated fatty acids. Curr. Opin. Clin. Nutr. Metab. Care 10: 427-432.
29. Dutta J., Fan Y., Gupta N., Fan G. & Gelinas C. 2006. Current insights into the regulation of programmed cell death by NF-κB. Oncogene 25: 6800-6816.
30. Femia A. P., Luceri C., Dolara P., Giannini A., Biggeri A., Salvadori M., Clum Y., Collins K. J., Paglierani M. & Caderni G. 2002. Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats. Carcinogenesis 23: 1953-1960.
31. Ferenčík M., Ebringer L. & Mikeš Z. 1999. Beneficial modification of the human intestinal microflora using orally administered lactic acid bacteria. Bratisl. Lek. Listy 100: 238-245.
32. Fosslien E. 2001. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann. Clin. Lab. Sci. 31: 325-347.
33. Fritsche K. L., Alexander D. W., Cassity N. A. & Huang S. C. 1993. Maternally-supplied fish oil alters piglet immune cell fatty acid profile and eicosanoid production. Lipids 28: 677-682.
34. Fuller R. 1992. The effect of probiotics on the gut microbiology of farm animals, pp. 171-192. In: Wood B. J. B. (ed.) The Lactic Acid Bacteria. Elsevier, London.
35. Garrett M. D. 2001. Cell cycle control and cancer. Curr. Sci. 81: 515-522.
36. Gibson G. R. & Roberfroid M. B. 1995. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J. Nutr. 125: 1401-1412.
37. Giovannini C., Scazzocchio B., Vari R., Santangelo C., D'Archivio M. & Masella R. 2007. Apoptosis in cancer and atherosclerosis: polyphenol activities. Ann. Ist. Super Sanita 43: 406-416.
38. Goldin B. R., Gualtieri L. & Moore R. P. 1996. The effect of Lactobacillus GG on the initiation and promotion of dimethylhydrazine-induced intestinal tumors in the rat. Nutr. Cancer 25: 197-204.
39. Gong L., Li Y., Nedeljkovic-Kurepa A. & Sarkar F. H. 2003. Inactivation of NF-κB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 22: 4702-4709.
40. Grana X. & Reddy E. P. 1995. Cell cycle control inmammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclindependent kinase inhibitors (CKIs). Oncogene 11: 211-219.
41. Harris W. S., Connor W. E., Inkeles S. B. & Illingworth D. R. 1984. Dietary ω-3 fatty acids prevent carbohydrate-induced hypertriglyceridemia. Metabolism 33: 1016-1019.
42. Higdon J. V. & Frei B. 2003. Tea catechins and polyphenols: health effects, metabolism and antioxidant functions. Crit. Rev. Food Sci. Nutr. 43: 89-143.
43. Hijová E., Chmelárová A., Bomba A. & Žitňan R. 2009. Prebiotic foodstuff and their health benefits in experiment. Bratisl. Lek. Listy 110: 523-525.
44. Hirayama V. & Rafter J. 2000. The role of probiotic bacteria in cancer prevention. Microbes Infect. 2: 681-686.
45. Hughes E., McCracken M., Roberts H., Mokdad A. H., Valluru B., Goodson R., Dunn E., Elam-Evans L., Giles W. & Jiles R. 2004. Surveillance for certain health behaviors among states and selected local areas-behavioral risk factor surveillance system. United States. MMWR Surveill. Summ. 55: 1-124.
46. Hull M. & Kant P. 2010. Atherosclerosis and colorectal carcinogenesis: shared risk factors or common pathogenesis? Digestion 81: 16-17.
47. Hussain S. P., Hofseth L. J. & Harris C. C. 2003. Radical causes of cancer. Nat. Rev. Cancer 3: 276-285.
48. Isolauri E., Kalliomäki M., Laitinen K. & Salminen S. 2008. MModulation of the maturing gut barrier and microbiota: a novel target in allergic disease. Curr. Pharm. Des. 14: 1368-1375.
49. Jackson K. G. & Lovegrove J. A. 2004. Functional food, blood lipids and cardiovascular disease. Part 2 - Prebiotics and synbiotics. Agro Food Industry Hi-Tech 15: 37-39.
50. Jazet I. M. & Meinders A. E. 2007. Adiponectin, role in insulin resistance, atherosclerosis and carcinogenesis. Ned. Tijdschr. Klin. Chem. Labgeneesk 32: 8-12.
51. Karin M., Yamamoto Y. & Wang Q. M. 2004. The IKK NF-κB system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3: 17-26.
52. Kašteľ R., Bindas Ľ., Magic D., Bomba A., Vaško L., Horváth M. & Šajbidor J. 1999. Growth dynamics and metabolic parameters in piglets supplemented with oil with higher content of n-3 PUFA. Folia Veterinaria 43: 176-181.
53. Kašteľ R., Bomba A., Vaško L. Trebuňová A. & Mach P. 2007. The effect of probiotics potentiated by polyunsaturated fatty acids on the digestive tract of germ-free piglets. Vet. Med. 52: 63-68.
54. Khailova L., Mount Patrick S. K., Arganbright K. M., Halpern M. D., Kinouchi T. & Dvorak B. 2010. Bifidobacterium bi-fidum reduces apoptosis in the intestinal epithelium in necrotizing enterocolitis. Am. J. Physiol. Gastrointestinal Liver Physiol. 299: 1118-1127.
55. Kim Y. G., Ohta T., Takahashi T., Kushiro A., Nomoto K., Yokokura T., Okada N. & Danbara H. 2006. Probiotic Lactobacillus casei activates innate immunity via NF-κB and p38 MAP kinase signaling pathways. Microb. Infect. 8: 994-1005.
56. Kirton J. P., Crofts N. J., George S. J., Brennan K. & Canfield A. E. 2007. Wnt/β-catenin signaling stimulates chondrogenic and inhibits adipogenic differentiation of pericytes: potential relevance to vascular disease? Circ. Res. 101: 581-589.
57. Klaunig J. E. & Kamendulis L. M. 2004. The role of oxidative stress in carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 44: 239-267.
58. Koprovičová J., Chmelárová A., Strojný L. & Bomba A. 2010. Influence of prebiotic fibre supplementation and probiotics on serum lipids in rats, pp. 133-134. In: Proceedings of International Scientific Conference on Probiotics and Prebiotics IPC 2010, Košice, Slovakia.
59. Kris-Etherton P. M., Hecker K. D., Bonanome A., Coval S. M., Binkoski A. E., Hilpert K. F., Griel A. E. & Etherton T. D. 2002. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am. J. Med. 113: 71-88.
60. Lamacka M. & Sajbidor J. 1995. The occurrence of prostaglandins and related compounds in lower organisms. Prostaglandins Leukot. Essent. Fatty Acids 52: 357-364.
61. Law M. R. & Morris J. K. 1998. By how much does fruit and vegetable consumption reduce the risk of ischemic heart disease? Eur. J. Clin. Nutr. 52: 549-556.
62. Leaf A., Kang J. X., Xiao Y. & Billman G. 2003. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 107: 2646-2652.
63. Lim M. Y., Wang H., Kapoun A. M., O'Connell M., O'Young G., Brauer H. A., Luedtke G. R., Chakravarty S., Dugar S., Schreiner G. S., Protter A. A. & Higgins L. S. 2004. p38 inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells. J. Mol. Cell. Cardiol. 37: 1111-1114.
64. Limdi J. K., O'Neill C. & McLaughlin M. C. 2006. Do probiotics have a therapeutic role in gastroenterology? World J. Gastroenterol. 12: 5447-5457.
65. Lindbeck A., Overvik E., Rafter J., Nord C. E. & Gustafsson J. A. 1992. Effect of Lactobacillus acidophilus supplements on mutagen excretion in faeces and urine in humans. Microb. Ecol. Health Dis. 5: 59-67.
66. Ling-Amster H., Rochat F., Saudan K. Y., Mignot O. & Aeschlimann J. M. 1994. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol. Med. Microbiol. 10: 55-63.
67. Liong M. T. 2008. Roles of probiotics and prebiotics in colon cancer prevention: postulated mechanisms and in-vivo evidence. Int. J. Mol. Sci. 9: 854-863.
68. Lovegrove J. A. & Jackson K. G. 2004. Functional food, blood lipids and cardiovascular disease. Part 1 - Probiotics. Agro Food Industry Hi-Tech 15: 50-52.
69. Martin S., Giannone G., Andriantsitohaina R. & Martinez M. C. 2003. Delphinidin, an active compound of red wine, inhibits endothelial cell apoptosis via nitric oxide pathway and regulation of calcium homeostasis. Br. J. Pharmacol. 139: 1095-1102.
70. Masella R., Vari R., D'Archivio M., Di Benedetto R., Matarrese P., Malorni W., Scazzocchio B. & Giovannini C. 2004. Extra virgin olive oil biophenols inhibit cell-mediated oxidation of LDL by increasing the mRNA transcription of glutathione-related enzymes. J. Nutr. 134: 785-791.
71. Massague J. 2008. TGFβ in cancer. Cell 134: 215-230.
72. Mojžiš J. & Mojžišová G. 2001. Flavonoids and their biological effects. Vienala, Košice, 134 pp.
73. Mojžišová G. & Mojžiš J. 2008. Flavonoids and their potential health benefits: relation to heart disease and cancer, pp. 105-129. In: Singh M. V. K. & Govil J. N. (eds) Phytopharmacology and Therapeutic Values. Studium Press, Houston.
74. Monaco C. & Paleolog E. 2004. Nuclear factor κB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc. Res. 61: 671-682.
75. Moon H. K., Yang E. S. & Park J. W. 2006. Protection of peroxynitrite-induced DNA damage by dietary antioxidants. Arch. Pharm. Res. 29: 213-217.
76. Morganti M., Carpi A., Nicolini A., Gorini I., Glaviano B., Fini M., Giavaresi G., Mittermayer C. & Giardino R. 2002. Atherosclerosis and cancer: common pathways on the vascular endothelium. Biomed. Pharmacother. 56: 317-324.
77. Nam S., Smith D. M. & Dou Q. P. 2003. Tannic acid potently inhibits tumor cell proteasome activity, increases p27 and Bax expression, and induces G1 arrest and apoptosis. Cancer Epidemiol. Biomarkers Prev. 10: 1083-1088.
78. Nestel P. J. 1986. Fish oil attenuates the cholesterol induced rise in lipoprotein cholesterol. Am. J. Clin. Nutr. 43: 752-757.
79. Niederberger E. & Geisslinger G. 2010. Analysis of NF-κB signaling pathways by proteomic approaches. Expert Rev. Proteomics 7: 189-203.
80. Oberreuther-Moschner D. L, Jahreis G., Rechkemmer G. & Pool-Yobel B. L. 2004. Dietary intervention with the probiotics Lactobacillus acidophilus 145 and Bifidobacterium longum 913 modulates the potential of human faecal water to induce damage in HT29clone19A cells. Br. J. Nutr. 91: 925-932.
81. Olinski R., Gackowski D., Foksinski M., Rozalski R., Roszkowski K. & Jaruga P. 2002. Oxidative DNA damage: assessment of the role in carcinogenesis, atherosclerosis and acquired immunodeficiency syndrome. Free Radical Biol. Med. 33: 192-200.
82. Olsen E. & Lien A. M. 2008. Omega-3 and health. Marine ω-3 fatty acids and their effects on development, growth, and diseases. Agro Food Industry Hi-Tech 19: 80-82.
83. Ouwehand A. C., Salminen S. & Isolauri E. 2002. Probiotics: an overview of beneficial effects. Antonie van Leeuwenhoek 82: 279-289.
84. Pahl H. L. 1999. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18: 6853-6866.
85. Parvez S., Malik K. A., Kang S. A. & Kim H. Y. 2006. Probiotics and their fermented food products are beneficial for health. J. Appl. Microbiol. 100: 1171-1185.
86. Peters U., Poole C. & Arab L. 2001. Does tea affect cardiovascular disease? A meta-analysis. Am. J. Epidemiol. 154: 495-503.
87. Rafter J. 2002. Lactic acid bacteria and cancer: mechanistic perspective. Br. J. Nutr. 88(Suppl. 1): 89-94.
88. Rafter J., Bennett M., Caderni G., Clune Y., Hughes R., Karlsson P. C., Klinder A., O'Riordan M., O'sullivann G. C., Pool-Zobel B., Rechkemmer G., Roller M., Rowland I., Salvadori M., Thijs H., van Loo J., Watzl B. & Collins J. K. 2007. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Amer. J. Clin. Nutr. 85: 488-496.
89. Raitano A. & Korc M. 1993. Growth inhibition of human colorectal carcinoma cell line by interleukine-1 is associated with enhanced expression of γ-interferon receptors. Cancer Res. 53: 634-640.
90. Ramos K. S. & Partridge C. R. 2005. Atherosclerosis and cancer: flip sides of the neoplastic response in mammalian cells? Cardiovasc. Toxicol. 5: 245-255.
91. Ranganna K., Yatsu F. M., Hayes B. E., Milton S. G. & Jayakumar A. 2000. Butyrate inhibits proliferation-induced proliferating cell nuclear antigen expression (PCNA) in rat vascular smooth muscle cells. Mol. Cell. Biochem. 205: 149-161.
92. Rault-Nania M. H., Gueux E., Demougeot C., Demigne C., Rock E. & Mazur A. 2006. Inulin attenuates atherosclerosis in apolipoprotein E-deficient mice. Br. J. Nutr. 96: 840-844.
93. Reddy B. S., Hamid R. & Rao C. V. 1997. Effect of dietary oligofructose and inulin on colonic preneoplastic aberrant crypt foci inhibition. Carcinogenesis 19: 1371-1374.
94. Redondo S., Santos-Gallego C. G. & Tejerina T. 2007. TGF-β1: a novel target for cardiovascular pharmacology. Cytokine Growth Factor Rev. 18: 279-286.
95. Ren W., Qido Z., Wang H., Zhu L. & Zhang L. 2003. Flavonoids: promising anticancer agents. Med. Res. Rev. 23: 519-534.
96. Ross J. S., Stagliano N. E., Donovan M. J., Breitbart R. E. & Ginsburg G. S. 2001. Atherosclerosis and cancer: common molecular pathways of disease development and progression. Ann. N. Y. Acad. Sci. 947: 271-292.
97. Rowland I. R., Rumney C. J., Coutts J. T. & Lievense L. C. 1998. Effect of Bifidobacerium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis 19: 281-285.
98. Saikali J., Picard V., Freitas M. & Holt P. R. 2004. Fermented milks, probiotic cultures, and colon cancer. Nutr. Cancer 49: 14-24.
99. Sherr C. J. 1996. Cancer cell cycles. Science 274: 1672-1677.
100. Singh N. N & Ramji D. P. 2006. The role of transforming growth factor-β in atherosclerosis. Cytokine Growth Factor Rev. 17: 487-499.
101. Studer M., Briel M., Liemenstoll B., Blass T. R. & Bucher H. C. 2005. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch. Intern. Med. 165: 725-730.
102. Sun J., Shi Y. H., Le G. W. & Ma X. Y. 2005. Distinct immune response induced by peptidoglycan derived from Lactobacillus sp. World J. Gastroenterol. 11: 6330-6337.
103. Takagi A., Matsuzaki T., Sato M., Nomoto K., Morotomi M. & Yokokura T. 2001. Enhancement of natural killer cytotoxicity delayed murine carcinogenesis by a probiotic microorganism. Carcinogenesis 22: 599-605.
104. Takeuchi H., Maehara Y., Tokunaga E., Koga T., Kakeji Y. & Sugimachi K. 2001. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am. J. Gastroenterol. 96: 574-578.
105. Theodoratou E., McNeill G., Cetnarsky R., Farrington S. M., Tenesa A., Barnetson R., Porteous M., Dunlop M. & Campbell H. 2007. Dietary fatty acids and colorectal cancer: a case-control study. Am. J. Epidemiol. 166: 181-185.
106. Tinhofer I., Bernhard D., Senfter M., Anether G., Loeffler M., Kroemer G., Kofler R., Csordas A. & Greil R. 2001. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. FASEB J. 15: 1613-1615.
107. Tlaskalová-Hogenová H., Štepanková R., Kozáková H., Hudcovic T., Vannucci L., Tučková L., Rossmann P., Hrnčíř T., Kverka M., Zákostelská Z., Klimešová K., Přibylová J., Bártová J., Sanchez D., Fundová P., Borovská D., Šrútková D., Zídek Z., Schwarzer M., Drastich P. & Funda D. P. 2011. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol. Immunol. 8: 110-120.
108. van Baarlen P., Troost F., van der Meer C., Hooiveld G., Boekschoten M., Brummer R. J. & Kleerebezem M. 2011. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc. Natl. Acad. Sci. USA 108(Suppl. 1): 4562-4569.
109. Veeman M. T., Axelrod J. D. & Moon R. T. 2003. A second canon. Functions and mechanisms of β-catenin-independent Wnt signaling. Dev. Cell 5: 691-701.
110. Visse R. & Nagase H. 2003. Matrix metalloproteinases and tissue inhibitors of met-alloproteinases structure, function, and biochemistry. Circ. Res. 92: 827-839.
111. Westermark J. & Kahari V. M. 1999. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13: 781-792.
112. Wollowski I., Rechkemmer G. & Pool-Zobel B. L. 2001. Protective role of probiotics and prebiotics in colon cancer. Am. J. Clin. Nutr. 73: 451-455.
113. World Health Organization. 2001. Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Joint WHO/FAO Expert Consultation on Geneva: WHO.
114. Wu F. T., Stefanini M. O., Mac Gabhann F., Kontos C. D., Annex B. H. & Popel A. S. 2010. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J. Cell Mol. Med. 14: 528-552.
115. Wu H., Dwyer K. M., Fan Z., Shircore A., Fan J. & Dwyer J. H. 2003. Dietary fiber and progression of atherosclerosis: the Los Angeles atherosclerosis study. Am. J. Clin. Nutr. 78: 1085-1091.
116. Yamamoto Y., Gaynor R. B. 2004. IκB kinases: key regulators of the NF-κB pathway. Trends Biochem. Sci. 29: 72-79.
117. Yoon S. O., Park S. J., Yun C. H & Chung A. S. 2003. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J. Biochem. Mol. Biol. 36: 128-137.
118. Zacconi C., Bottazzi V., Rebecchi A., Bosi E., Sarra P. G. & Tagliaferi L. 1992. Serum cholesterol levels in axenic mice colonized with Enterococcus faecium and Lactobacillus acidophilus. Microbiologica 15: 413-418.
119. Zarubin T. & Han J. 2005. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 15: 11-18.
120. Zern T. L. & Fernandez M. L. 2005. Cardioprotective effects of dietary polyphenols. J. Nutr. 135: 2291-2294.